ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief Financial Officer & Chief Bu...
July 15 2014 - 9:00AM
Business Wire
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines that address unmet medical needs in
neurological and related central nervous system disorders,
announced the appointment of Stephen Davis as Executive Vice
President, Chief Financial Officer and Chief Business Officer,
effective today. Mr. Davis will report to Uli Hacksell, Ph.D.,
ACADIA’s Chief Executive Officer.
“Steve is a highly accomplished industry executive with
extensive financial and operational experience, and will be an
outstanding addition to our team,” said Dr. Hacksell. “Steve’s
impressive background and demonstrated leadership skills will be
key as we continue to build the corporate infrastructure necessary
to support the planned launch of pimavanserin in Parkinson’s
disease psychosis and seek to maximize the significant
opportunities ahead for pimavanserin.”
Mr. Davis brings over 20 years of executive-level experience in
the pharmaceutical industry. He most recently served as Executive
Vice President and Chief Operating Officer at Heron Therapeutics,
Inc., which he joined in 2013. He led core business and finance
functions there and was instrumental in developing and implementing
a new corporate strategy with a multi-program portfolio.
Previously, Mr. Davis served as Executive Vice President and Chief
Operating Officer at Ardea Biosciences, Inc. from 2010 to 2013,
where he oversaw business functions, including finance, commercial
planning, and corporate development, and played a critical role in
building and growing the company. Prior to joining Ardea, Mr. Davis
served in numerous executive roles at Neurogen Corporation from
1994 to 2010, including Chief Financial Officer, Chief Operating
Officer, and Chief Executive Officer, completing multiple
collaborations and product acquisitions with global pharmaceutical
companies. Mr. Davis currently serves on the Board of Directors of
Heron Therapeutics and Synageva BioPharma Corp.
Earlier in his career, Mr. Davis practiced as a Certified Public
Accountant with a major accounting firm and as a corporate and
securities attorney with a Wall Street law firm. Mr. Davis received
his Bachelor of Science degree in Accounting from Southern Nazarene
University and a J.D. from Vanderbilt University.
“This is an exciting time to join ACADIA as it advances
pimavanserin toward an NDA submission, prepares for the planned
launch of pimavanserin, and strategically expands the program into
other important neurological and psychiatric indications,” said Mr.
Davis. “I look forward to being part of a high-caliber team that
shares the vision of building a leading U.S. specialty neurology
company.”
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines that address unmet
medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by
pimavanserin, which is in Phase III development as a potential
first-in-class treatment for Parkinson’s disease psychosis.
Pimavanserin is also in Phase II development for Alzheimer’s
disease psychosis and has successfully completed a Phase II trial
as a co-therapy for schizophrenia. ACADIA also has clinical-stage
programs for chronic pain and glaucoma in collaboration with
Allergan, Inc. and two advanced preclinical programs directed at
Parkinson’s disease and other neurological disorders. All product
candidates are small molecules that emanate from internal
discoveries. ACADIA maintains a website at www.acadia-pharm.com to
which ACADIA regularly posts copies of its press releases as well
as additional information and through which interested parties can
subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements related to the
progress, expansion and timing of ACADIA’s drug discovery and
development programs, either alone or with a partner, including
clinical trials, the potential benefits to be derived from ACADIA’s
product candidates, in each case including pimavanserin, any future
approval or launch of pimavanserin for Parkinson’s disease
psychosis or any other indication, any expansion or significant
opportunities ahead for the pimavanserin program, ACADIA’s growth,
or the ability of ACADIA to become a leading U.S. specialty
neurology company. These statements are only predictions based on
current information and expectations and involve a number of risks
and uncertainties. Actual events or results may differ materially
from those projected in any of such statements due to various
factors, including the risks and uncertainties inherent in drug
discovery, development and commercialization, and collaborations
with others, and the fact that past results of clinical trials may
not be indicative of future trial results. For a discussion of
these and other factors, please refer to ACADIA’s annual report on
Form 10-K for the year ended December 31, 2013 as well as ACADIA’s
subsequent filings with the Securities and Exchange Commission. You
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is
made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are
qualified in their entirety by this cautionary statement and ACADIA
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as
required by law.
ACADIA Pharmaceuticals Inc.Uli Hacksell, Ph.D., Chief Executive
OfficerLisa Barthelemy, Director of Investor Relations(858)
558-2871
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024